Compare GSK plc (GSK) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Paycom Software Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Paycom Software Inc trades at $232.22 (market cap $10.36B). The key difference: GSK plc is far larger — about 8.9× Paycom Software Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Paycom Software Inc for 84 Days on average.
| GSK | PAYC | |
|---|---|---|
Market Cap | $91.88B | $10.36B |
Volume | 7,730,529 | 666,294 |
Sector | Health | Technology |
52-Week High | $61.18 | $240.52 |
52-Week Low | $43.24 | $113.59 |
Typical Hold Time | 93 Days | 84 Days |
Enterprise Value | $111.88B | $11.15B |
Dividend Yield | 3.9% | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Paycom Software (PAYC) trades at $229.90, up 2.83% today, showing strong momentum after beating Q2 2026 earnings expectations with EPS of $2.78 versus $2.38 expected. The stock demonstrates robust fundamentals with 22.78% net income margin and 41.09% ROE, though valuation metrics like P/E of 24.33 and P/S of 5.6 appear elevated. Technical indicators show bullish momentum with the current price trading above key support levels, while analyst sentiment remains mixed with 47% buy ratings.
PAYC presents a growth opportunity with consistent earnings beats and raised 2026 guidance targeting 7-8% revenue growth, but faces risks from premium valuation and competitive pressures in payroll software. The stock's recent institutional buying activity and strong cash flow generation support the bullish case, though investors should monitor execution against guidance and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
